Reuptake

Reuptake is the process by which a neurotransmitter is drawn back into the neuron that released it, ending the signal it was carrying. Specialised transport proteins in the cell membrane retrieve the chemical messenger from the synapse — the gap between neurons — and return it for reuse or breakdown.

The concept matters across pharmacology because a large class of psychoactive substances works by interfering with this retrieval step. Blocking a transporter leaves more neurotransmitter in the synapse for longer, amplifying and extending its signal.

How it is done

Each major neurotransmitter has a dedicated transporter. The SERT (SERT) handles serotonin; the DAT (DAT) handles dopamine; the NET (NET) handles norepinephrine. When a drug binds to and blocks one of these proteins, the neurotransmitter it normally retrieves accumulates in the synapse instead.

Different drugs act on different transporters with different selectivity. SSRIs target SERT almost exclusively, raising synaptic serotonin gradually over days to weeks. Cocaine blocks all three transporters simultaneously. MDMA not only blocks SERT but runs the transporter in reverse, actively pushing serotonin into the synapse rather than simply preventing its retrieval — a faster and larger shift.

Some substances described as reuptake inhibitors act broadly across several transporters; others are highly selective. The label does not specify which.

What it cannot tell you

Knowing that a drug inhibits reuptake does not establish what it does in combination with other substances that act on the same neurotransmitter systems.

The most common wrong conclusion is that two reuptake inhibitors can be combined safely because they share a mechanism, or that their effects are simply additive. The interaction between MAOI-class drugs and serotonin reuptake inhibitors illustrates why this reasoning fails: combining them can produce serotonin syndrome at doses that are ordinary for each individually. The mechanism category does not predict this.

Reuptake inhibition also says nothing about receptor-level activity, release mechanisms, or downstream effects. A substance can raise synaptic serotonin while simultaneously acting as an antagonist at serotonin receptors — producing an overall effect that the transporter mechanism alone cannot account for.

Interaction risk belongs in the interaction layer of each substance record, where it is evaluated alongside its sources. A shared transporter target is a signal to check that layer, not a basis for inferring safety.